🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

635 results for “dose” Clear

  1. Single dose, open-label, laboratory blinded, randomized, 2-treatment, 2-period, 2-sequence, crossover, pivotal study to assess the relative bioavailability of Test Product Naproxen sodium 660 mg modified release tablets to Reference Product Actromadol 660 mg Modified-Release tablets in healthy adult male and female subjects under fasting conditions.s.

    Laboratorios Tillomed Spain S.L.U

    Bioavailability study in healthy volunteers under fasting conditions.

    phase 1 other active

    1 trial

  2. Single microdose trial - CXCR4 PET tracer - Pharmacokinetics and pharmacodynamics of [68Ga]Ga-R54, a CXCR4-targeted radiopharmaceutical in patients with advanced solid tumors.

    Fondazione Telethon ETS

    Advanced solid neoplasm (breast, lung, colon, ovary, pancreas) characterized by positive CXCR4 expression by immunohistochemistry

    phase 1 other active

    1 trial

  3. Single-Ascending Doses of 2-Methoxyestradiol in Healthy Non-Pregnant Female Subjects.

    Laboratorios Tillomed Spain S.L.U

    No medical condition.

    phase 1 other active

    1 trial

  4. Single-Dose Study in Healthy Participants to Compare the Bioavailability of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg versus One Film-Coated Tablet of Indapamide IR 2.5 mg Under Fasting Conditions, and to Compare the Bioavailability of One Film-Coated Mini-Tablet of Indapamide SR 1.5 mg Under Fasting versus Fed Conditions.

    The George Institute

    No medical condition.

    phase 1 other active

    1 trial

  5. Single-center, single-dose, open-label, laboratory-blinded, randomized, two-treatment, two-period bioequivalence (BE) study comparing the Test Product Apixaban 5 mg film-coated tablets (MEDITOP) with the Reference Product Eliquis 5 mg film-coated tablets (Bristol-Myers Squibb/Pfizer) under fasting conditions.

    Pari Pharma GmbH

    Comparative bioequivalence study in healthy volunteers under fasting conditions.

    phase 1 other active

    1 trial

  6. Study to evaluate the safety, tolerability, maximum tolerated dose and clinical activity of TNB-383B when given to patients with multiple myeloma

    AbbVie Deutschland GmbH & Co. KG

    Relapsed or refractory multiple myeloma

    phase 1 other active

    1 trial

  7. TAK-058 (ENV8058)

    Takeda

    Dose Finding Study

    phase 1 small molecule completed

    1 trial

  8. TAK-137

    Takeda

    Dose Finding Study

    phase 1 small molecule completed

    1 trial

  9. TAK-438

    Takeda

    Ascending Single Dose Study

    phase 1 small molecule completed

    1 trial

  10. TAK-438

    Takeda

    Dose Finding Study

    phase 1 small molecule completed

    2 trials

  11. TAK-828

    Takeda

    Dose Finding Study

    phase 1 small molecule completed

    1 trial

  12. TD-1211 Dose 1

    Theravance Biopharma Ireland Umited

    Constipation

    phase 1 small molecule completed

    1 trial

  13. TD-1473 - Dose A

    Theravance Biopharma Ireland Umited

    Inflammatory Bowel Diseases

    phase 1 small molecule completed

    1 trial

  14. TDV - Low Dose

    Takeda

    Dengue Fever

    phase 1 mab completed

    1 trial

  15. TGD001 SAD study in healthy volunteers

    Lacuna Pharma Pty Ltd

    A Phase I randomized, double-blind, placebo-controlled study to assess the safety and pharmacokinetics of single-ascending doses of TGD001 in healthy volunteers

    phase 1 other active

    1 trial

  16. THC High Dose

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Use

    phase 1 small molecule active

    1 trial

  17. The 10mg dose group

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  18. This study aims to find the best dose of BI 907828 (brigimadlin) in patients with different types of advanced cancer (solid tumors)

    Boehringer Ingelheim

    Advanced or metastatic solid tumors

    phase 1 other active

    1 trial

  19. ThisCART19A with Dose Level 1

    The First People's Hospital of Lianyungang

    CAR

    phase 1 small molecule active

    1 trial

  20. To assess the relative BA of a low-strength FDC tablet formulation of niraparib plus AA compared to niraparib and AA co-administered as single agents after single dose administration and to assess BE of a regular strength FDC tablet formulation of niraparib plus AA compared to niraparib and AA co-administered as single agents at steady state in men with prostate cancer

    Janssen-Cilag International N.V.

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 1 other active

    1 trial

  21. Two doses of middle-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28

    Jiangsu Province Centers for Disease Control and Prevention

    COVID-19

    phase 1 mab completed

    1 trial

  22. Volasertib, low dose, d1q3w

    Boehringer Ingelheim

    Neoplasms

    phase 1 small molecule completed

    1 trial

  23. a 60 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 30-mg tablets (Treatment A) or one 60-mg tablet (Treatment B).

    Teva Pharma GmbH

    Pain

    phase 1 small molecule completed

    1 trial

  24. high-dose Group ACYW135X Meningococcal Conjugate Vaccine

    Sinovac Research and Development Co.,

    Meningococcal Meningitis

    phase 1 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources